SEC Tracker
Get the app

BeyondSpring BYSI

BeyondSpring completes asset sale

Form
8-K
Filed
Importance
Routine
  1. Completed sale of BeyondSpring Ltd. to Biolin Investment Limited on Sep 30, 2026
  2. No cash consideration paid, non-cash consideration includes data rights and trial funding
  3. Pro forma financials show $53.7M gain on disposal
  4. Company no longer controls subsidiaries including Bulin and SEED

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when BeyondSpring files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Corbus Pharmaceuticals Holdings CRBP public float $68M, Jun 30, 2025
  2. Seres Therapeutics MCRB public float $72M, Jun 30, 2025
  3. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  4. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  5. Volitionrx VNRX public float $73M, Jun 30, 2025